1. Inici
  2. Publicacions
  3. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Prat, A
  • Lluch, A
  • Albanell, J
  • Barry, WT
  • Fan, C
  • Chacon, JI
  • Parker, JS
  • Calvo, L
  • Plazaola, A
  • Arcusa, A
  • Segui-Palmer, MA
  • Burgues, O
  • Ribelles, N
  • Rodriguez-Lescure, A
  • Guerrero, A
  • Ruiz-Borrego, M
  • Lopez, JA
  • Adamo, B
  • Cheang, MCU
  • Li, Y
  • Hu, Z
  • Gulley, ML
  • Vidal, MJ
  • Pitcher, BN
  • Liu, MC
  • Citron, ML
  • Ellis, MJ
  • Mardis, E
  • Vickery, T
  • Hudis, CA
  • Winer, EP
  • Carey, LA
  • Caballero, R
  • Carrasco, E
  • Martin, M
  • Perou, CM
  • Alba, E

Abstract

Background: In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer (TNBC). Methods: Gene expression and clinical-pathological data were evaluated in five independent cohorts, including three randomised clinical trials for a total of 1055 patients with TNBC, basal-like disease (BLBC) or both. Previously defined intrinsic molecular subtype and a proliferation signature were determined and tested. Each signature was tested using multivariable logistic regression models (for pCR (pathological complete response)) and Cox models (for survival). Within TNBC, interactions between each signature and the basal-like subtype (vs other subtypes) for predicting either pCR or survival were investigated. Results: Within TNBC, all intrinsic subtypes were identified but BLBC predominated (55-81%). Significant associations between genomic signatures and response and survival after chemotherapy were only identified within BLBC and not within TNBC as a whole. In particular, high expression of a previously identified proliferation signature, or low expression of the luminal A signature, was found independently associated with pCR and improved survival following chemotherapy across different cohorts. Significant interaction tests were only obtained between each signature and the BLBC subtype for prediction of chemotherapy response or survival. Conclusions: The proliferation signature predicts response and improved survival after chemotherapy, but only within BLBC. This highlights the clinical implications of TNBC heterogeneity, and suggests that future clinical trials focused on this phenotypic subtype should consider stratifying patients as having BLBC or not.

Dades de la publicació

ISSN/ISSNe:
0007-0920, 1532-1827

BRITISH JOURNAL OF CANCER  NATURE PUBLISHING GROUP

Tipus:
Article
Pàgines:
1532-1541
PubMed:
25101563
Factor d'Impacte:
2,622 SCImago ℠
Quartil:
Q1 SCImago ℠

Cites Rebudes en Web of Science: 82

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • breast cancer; genomics; subtypes; intrinsic; basal like; chemotherapy; neoadjuvant

Campos d'Estudi

Projectes associats

ESTUDIO DE FASE II MULTICENTRICO ALEATORIZADO PARA COMPARAR LA COMBINACION DE TRASTUZUMAB Y CAPECITABINA, CON O SIN PERTUZUMAB, EN PACIENTES CON CANCER DE MAMA METASTASICO POSITIVO PARA HER2 QUE HAYAN PROGRESADO TRAS UNA LINEA DE TRATAMIENTO BASADO EN TRA SZUMAB EN EL CONTEXTO METASTASICO (PHEREXA).

Investigador Principal: ANA SANTABALLA BERTRÁN

MO22324 . 2010

ESTUDIO MULTICENTRICO FASE II DE DISTRIBUCION ALEATORIA, PARA EVALUAR LA EFICACIA DE TRATAMIENTO NEOADYUVANTE SELECTIVO SEGUN SUBTIPO INMUNOHISTOQUIMICO EN CANCER DE MAMA HER2 NEGATIVO.

Investigador Principal: ANA SANTABALLA BERTRÁN

GEICAM/2006-03

ESTUDIO DE FASE III PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE PAZOPANIB EN MONOTERAPIA FRENTE A PLACEBO ENTRE MUJERES CON CANCER EPITELIAL DE OVARIO, DE TROMPA DE FALOPIO O PERITONEAL PRIMARIO QUE NO HAYAN PROGRESADO DESPUES DE LA QUIMIOTERAPIA DE PRIMER A LINEA

Investigador Principal: ANA SANTABALLA BERTRÁN

AGO-OVAR16/VEG110655 . 2010

Compartir la publicació